Figure 4: Infarct Size Reduction Following Long-Term 4-Week Oral Administration of Canagliflozin

(A) In both diabetic ZDF and nondiabetic ZL rats, we found a significant reduction of infarct size compared with control. In nondiabetic rats, infarct size was reduced from 55 ± 7% to 27 ± 3% (p = 0.001; n = 6 to 8 per group). In the diabetic ZDF rats, a similar reduction of infarct size was also observed with infarct size reducing from 37 ± 3% to 20 ± 2% (p = 0.001; n = 6 to 8). There was a modest, but significant, difference in infarct size between control diet–treated ZL and ZDF rats (p = 0.04). (B) Area at risk in all groups was equivalent (p = NS; n = 6 to 8 per group). Cana = canagliflozin; IS:AAR = infarct size/area at risk ratio; ND = nonsignificant; Veh = vehicle; other abbreviations as in Figure 1.